QIMR Berghofer Medical Research Institute

Proactive news headlines including Green Critical Minerals, Perpetual Resources, Recce Pharmaceuticals and International Graphite

Retrieved on: 
Thursday, December 15, 2022
Titan, Poseidon, Hydrogen, Lithium, Well, FWS, BRK, QPM, KZIA, RCE, AGC, JRL, NSW, QIMR Berghofer Medical Research Institute, TTM, POS, JSE, Forest and Rangeland Renewable Resources Planning Act of 1974, Research, Mining, AUT, Fever Dream, AOI, Black Swan Project, Endangered Species Act of 1973, Gold, Endangered species, EA, ESA, Knowledge, Proactivity, KTA, OTCQB, TSX, Canadian Environmental Protection Act, 1999, Murdoch Children's Research Institute, Wolfpack, ORN, AAJ, Institutional review board, SureFire, ASX, INR, PEC, IP, TMR, AAU, Environmental protection, OTC, BFS, MRE, Silicon dioxide, ILA, GCM, Research institute, Aluminium, Iron ore, Pharmaceutical industry, Oil, Uranium, Rare-earth element, Leonora

Click here

Key Points: 
  • Click here
    International Graphite Ltd (ASX:IG6) has intersected fresh areas of graphite mineralisation in a drilling program investigating the previously undrilled target SDE_1 at Springdale Graphite Project in Western Australia.
  • In 2020, Proactive featured in 809 million search results, our content was viewed over 165 million times and our readers spent over 10 million hours on our websites.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected].

AAV Manufacturing -- Overcoming the Challenges of Plasmid DNA, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 14, 2022
Food, AAV, University of Sydney, Safety, Drug development, Child, DNA, QIMR Berghofer Medical Research Institute, University, Challenge, Industry, Vaccine

TORONTO, Nov. 14, 2022 /PRNewswire-PRWeb/ -- AAV manufacturing and other types of advanced therapy production are experiencing challenges associated with their plasmid DNA supply. This includes slow or delayed production and poor DNA quality (owing to unstable or difficult sequences), impacting their ability to meet drug development timelines and regulatory demands.

Key Points: 
  • In this free webinar, learn about the challenges of plasmid DNA in AAV manufacturing and gain insights about the data and supportive case studies which introduce an alternative to plasmid DNA an enzymatic, antibiotic-free DNA vector called doggybone DNA.
  • TORONTO, Nov. 14, 2022 /PRNewswire-PRWeb/ -- AAV manufacturing and other types of advanced therapy production are experiencing challenges associated with their plasmid DNA supply.
  • In this webinar, the featured speakers will address the challenges of plasmid DNA in AAV manufacturing and present data and supportive case studies which introduce an alternative to plasmid DNA an enzymatic, antibiotic-free DNA vector called doggybone DNA (dbDNA).
  • For more information, or to register for this event, visit AAV Manufacturing Overcoming the Challenges of Plasmid DNA .

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

Retrieved on: 
Thursday, October 20, 2022
Exome sequencing, Communication, Records manager, Medicine, Accreditation, Government, Achievement, Science, Technology transfer, Laboratory, National Association of Testing Authorities, QIMR Berghofer Medical Research Institute, Patient, Hospital, Sequence, Exome, Research, National Association, Technology, Certification, TGA, Quality management, Therapeutic Goods Administration, Industry, NATA, Health, MGI, BGI Group, CEO, Intellectual property, Pathology, Compliance, Medical device

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.

Key Points: 
  • BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.
  • "We will continue to improve and increase the accessibility of clinical sequencing to clinical laboratories, research institutes and hospitals."
  • "The BGI Australia local staff are some of the highest quality I have worked with," said Dr Peter Kaub, a genetic pathologist and medical consultant to BGI Australia for clinical Whole Exome Sequencing.
  • "Receiving accreditation means that they can now service clinical Whole Exome Sequencing for any laboratories or hospitals that require it.

BGI Australia Receives NATA Certification for Clinical Whole Exome Sequencing

Retrieved on: 
Thursday, October 20, 2022
Exome sequencing, Communication, Records manager, Medicine, Accreditation, Government, Achievement, Science, Technology transfer, Laboratory, National Association of Testing Authorities, QIMR Berghofer Medical Research Institute, Patient, Hospital, Sequence, Exome, Research, National Association, Technology, Certification, TGA, Quality management, Therapeutic Goods Administration, Industry, NATA, Health, MGI, BGI Group, CEO, Intellectual property, Pathology, Compliance, Medical device

BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.

Key Points: 
  • BRISBANE, Australia, Oct. 20, 2022 /PRNewswire/ -- BGI Australia's lab has achieved accreditation from the National Association of Testing Authorities (NATA) to perform clinical Whole Exome Sequencingin Australia, paving the way for the global life sciences company to provide clinical sequencing services for identifyingpossible disease-causing genetic changes.
  • "We will continue to improve and increase the accessibility of clinical sequencing to clinical laboratories, research institutes and hospitals."
  • "The BGI Australia local staff are some of the highest quality I have worked with," said Dr Peter Kaub, a genetic pathologist and medical consultant to BGI Australia for clinical Whole Exome Sequencing.
  • "Receiving accreditation means that they can now service clinical Whole Exome Sequencing for any laboratories or hospitals that require it.

Elicio Therapeutics Presents Preclinical Data on AMP-CpG Adjuvant in Combination with EBV Vaccine at the 2022 Keystone Symposia: Viral Immunity: Basic Mechanisms and Therapeutic Applications

Retrieved on: 
Wednesday, July 6, 2022
Cell, Massachusetts Institute of Technology, Epstein–Barr virus, AMP, FDA, Translational medicine, Koch Institute for Integrative Cancer Research, Patient, Adult, QIMR, Research, Keystone Resort, Engineering, GLOBE, Laboratory, COVID-19, Population, Immunization, Cancer, Multiple sclerosis, Biomedicine, Immunoglobulin G, H. Lee Moffitt Cancer Center & Research Institute, Compliance, Epithelium, QIMR Berghofer Medical Research Institute, Immune system, Infection, Lymph, Partnership, Degenerative disease, Immunotherapy, MIT, Hematological Cancer Research Investment and Education Act, Immunology, EBV, CD8, HLA, KRAS, Darrell Irvin, Koch Institute, Biomedical engineering, Vaccine, Amplifier, Vaccination, Epitope, Safety, Therapy, Forward-looking statement, ISCB Senior Scientist Award, Pharmaceutical industry, Amphiphile, Elicio Berriz

The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.

Key Points: 
  • The data was presented at the 2022 Keystone Symposia on Viral Immunity Basic Mechanisms and Therapeutic Applications virtually and in-person at the Keystone Resort in Keystone, CO from June 29-July 2, 2022.
  • EBV is a herpesvirus responsible for the well-known mononucleosis infections (mono) and has also been implicated in multiple lymphoid and epithelial cancers.
  • EBV targets both B cells and epithelial cells and utilizes their molecular machinery to replicate the viral genome.
  • In preclinical models, we have observed lymph node-specific engagement driving therapeutic immune responses of increased magnitude, function and durability.

Proactive news headlines including Altech Chemicals, Dundas Minerals, Arovella Therapeutics and Sipa Resources

Retrieved on: 
Wednesday, April 20, 2022
Magnet, Lithium, BRU, Lead, Eye, AVL, ASX, Collection, GLOBE, OTCQX, Gold, UEP, Review, LOI, Central West, Mining, TSX, Malachite, LIT, C29, PFS, PRU, Natural killer T cell, OTC, Metal, MZZ, ATC, DUN, JDA, Australian Government, QIMR Berghofer Medical Research Institute, VRC, Recycling, Kingfisher, GHG, Proactivity, RC, RTR, REE, Zinc, AON, Copper, KFM, Soil, AS Dikaki, Joint, Oil, Rare-earth element, Electric battery

Click here

Key Points: 
  • Click here
    KGL Resources Ltd (ASX:KGL) has appointed experienced mining leader Steven Rooney as chief operations officer, effective from 2 May 2022.
  • Click here
    AuKing Mining Ltd (ASX:AKN) is out to raise $7.1 million via a two-tranche placement and rights issue.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Atara Biotherapeutics to Host EBV and MS Day

Retrieved on: 
Tuesday, March 15, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Bachelor of Science, Doctor of Philosophy, Twitter, MD, Stanford University, TCR, Research, Genetics, Lymphatic system, University, Multiple sclerosis, EBV, Patient, Review, Master of Science, ID, Northwest Biotherapeutics, Media, Canadian Aviation Regulations, Ottawa Hospital Research Institute, Hematological Cancer Research Investment and Education Act, Nasdaq, FRCPC, Antigen, Pediatrics, Degenerative disease, History, EDT, Neurology, Company, University of Ottawa, Multiple, Cancer, FAAN, ATRA, Epstein–Barr virus, HLA, Biology, QIMR Berghofer Medical Research Institute, MS, Autoimmune disease, LinkedIn, Investor, Vaccine, Management, Immunology

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 6:00 p.m. EDT.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, will host an EBV and multiple sclerosis (MS) Day on Tuesday, March 22, 2022 from 4:00 6:00 p.m. EDT.
  • A live webcast with accompanying slides can be accessed by visiting the Investors & Media News & Events section of atarabio.com .
  • Atara Biotherapeutics, Inc. ( @Atarabio ) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.
  • Atara is headquartered in South San Francisco and our leading-edge research, development and manufacturing facility is based in Thousand Oaks, California.

Published Study Details Proof-of-Concept for COVID-19 Detection via Saliva Screening

Retrieved on: 
Wednesday, February 23, 2022
Software, Networks, Hardware, Health, Electronic Design Automation, Medical Devices, Infectious Diseases, Technology, Development, ATR-FTIR, PCR, Cell, Twitter, Biomedical Advanced Research and Development Authority, Ethanol, Fourier-transform infrared spectroscopy, QIMR Berghofer Medical Research Institute, Saliva, COVID-19, Infection, Biomedicine, Airport, NYSE, QIMR, Workflow, FTIR, LinkedIn, Severe acute respiratory syndrome coronavirus 2, News, Prince, Area studies, Publication, Quality of life, Agilent Technologies, Solution, Software, 3D printing, Pharmaceutical industry, Vaccine, Research, Facebook

The researchers acquired infrared spectra of saliva samples following a quick and simple sample preparation requiring only ethanol and basic laboratory equipment.

Key Points: 
  • The researchers acquired infrared spectra of saliva samples following a quick and simple sample preparation requiring only ethanol and basic laboratory equipment.
  • An infrared spectrum can be considered as a biochemical snapshot of the saliva sample including a COVID-19 immune response signature.
  • Earlier research studies on ATR-FTIR for COVID-19 saliva testing were not conclusive on the biological basis for the saliva testing methodology.
  • The paper titled Pathophysiological Response to SARS-CoV-2 Infection Detected by Infrared Spectroscopy Enables Rapid and Robust Saliva Screening for COVID-19 has been published in the journal Biomedicines.

Cellevolve Announces Global Partnership with QIMR Berghofer Medical Research Institute to Advance Novel Off-the Shelf T-cell Therapy in the First Randomized Cell Therapy Trial for Progressive Multifocal Leukoencephalopathy (PML)

Retrieved on: 
Wednesday, December 1, 2021
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Patient, BK, Demyelinating disease, HLA, PML, CE, Human polyomavirus 2, NORD, Company, Immunodeficiency, Center, VST, Partnership, MD, JC, Match, MBA, QIMR Berghofer Medical Research Institute, IND, Progressive multifocal leukoencephalopathy, George Washington University School of Medicine & Health Sciences, Central nervous system, Doctor of Philosophy, ISCB Senior Scientist Award, BK virus, Therapy, Professor, Infrastructure as code, Washington University School of Medicine, Research, NASDAQ, Derrell, Social media, HIV disease progression rates, QIMR, FDA, Science, Regenerative medicine, Bio, Disease, Immunotherapy, Clinical Neuropharmacology, Pharmaceutical industry, Vaccine

Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.

Key Points: 
  • Cellevolve Bio (the Company or Cellevolve), a development and commercialization company focused on cell therapies, today announced a broad-based collaboration with Australia-based QIMR Berghofer Medical Research Institute and its cell therapy manufacturing facility Q-Gen Cell Therapeutics.
  • The initial therapeutic focus is on progressive multifocal leukoencephalopathy (PML), a demyelinating disease of the central nervous system caused by JC polyomavirus (JCPyV) occurring in immunocompromised patients.
  • We are honored to partner with leading VST researcher Professor Khanna and his team at QIMR Berghofer to advance a novel, bioengineered, JCV-specific off-the-shelf T-cell therapy to the clinic in this first randomized cell therapy clinical trial.
  • Cellevolve has received initial FDA feedback for its clinical development plan for the JCPyV VST (CE-VST01-JC) and IND submission is planned for the first half of 2022.

New Noninvasive Tests for Colon and Prostate Cancer Presented at the 2021 AACC Annual Scientific Meeting

Retrieved on: 
Tuesday, September 28, 2021
Blood, Cancer, DRS, Man, Serum, University of Tehran, Compliance, Medicine, Diagnosis, MicroRNA, Large intestine, Tehran University of Medical Sciences, BPH, Colorectal cancer, Patient, Biomarker, Prostate cancer, Saliva, Death, Occult blood, QIMR Berghofer Medical Research Institute, VEGF-A, Pain, Prostate, Technology, Prognosis, Time, G-CSF, Protein, Medical imaging

ATLANTA, Sept. 28, 2021 /PRNewswire/ -- Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively.

Key Points: 
  • ATLANTA, Sept. 28, 2021 /PRNewswire/ -- Two research teams have developed new noninvasive tests that use either blood or saliva samples to diagnose cases of colorectal cancer or prostate cancer, respectively.
  • Presented today at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo, these tests could facilitate screening efforts for colorectal cancer and allow clinicians to better distinguish early-stage prostate cancer from more benign prostate conditions.
  • Another challenge in cancer care is the diagnosis of prostate cancer, one of the most common cancers in men.
  • Clinicians currently use invasive biopsies or tests for prostate-specific antigen levels to diagnose prostate cancer in the clinic.